Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients

Conclusion IDH1 and IDH2 mutations are negative prognostic markers in AML patients. A novel mutation (R132V) was detected in IDH1 in our cohort of AML patients. We recommend molecular testing for IDH1 and IDH2 mutations for proper risk stratification of AML patients before the start of therapy. Micro-Abstract This study aimed to determine the frequencies and clinical impact of isocitrate dehydrogenase (IDH) 1 and IDH2 mutations among Egyptian acute myeloid leukemia (AML) patients. The exon 4 of IDH1 and IDH2 were sequenced for detection of mutations in 211 AML bone marrow samples. The IDH1 and IDH2 mutations were detected in 8.5%, and 10.4% respectively. IDH1 and IDH2 mutations are negative prognostic markers in AML patients. A novel mutation (R132V) was detected in IDH1 in our cohort of AML patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research